top of page
  • patricia5628

Nonprescription Intranasal Naloxone Approved by the FDA

Over the last 20 years it is estimated that over a million people have died from drug overdoses often associated with opioids. Post pandemic data indicate that opioid overdoses/deaths are increasing at a greater than previous rate and are now the leading cause of accidental death in the United States.

Today the FDA approved a nonprescription naloxone nasal spray packaged in two 4 mg doses by Emergent BioSolutions. The product should be available in pharmacies by late summer, 2023. While most States have a mechanism in place that allows pharmacists to provide treatment to at risk individuals without a personal prescription, approving an over the counter antidote will allow easier access and most definitely save lives.

7 views0 comments

Recent Posts

See All

A PGx test may be accomplished with a simple buccal swab. Each of us is unique - similarly how our body handles and responds to medication is unique. In many patients, PGx results can help to pinpoint

Advances in pharmacogenomics (PGx) - and our enhanced understanding of the individual variability of drug response - is transforming our approach to the treatment of disease. National Adverse Drug Eve

bottom of page